Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis | Zendy

Edel McDermott | Zendy; Seamus Murphy | Zendy; Denise Keegan | Zendy; Diarmuid P. O’Donoghue | Zendy; Hugh Mulcahy | Zendy; Glen Doherty | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis

Author(s) -

Edel McDermott,

Seamus Murphy,

Denise Keegan,

Diarmuid P. O’Donoghue,

Hugh Mulcahy,

Glen Doherty

Publication year - 2012

Publication title -

journal of crohn s and colitis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.277

H-Index - 80

eISSN - 1876-4479

pISSN - 1873-9946

DOI - 10.1016/j.crohns.2012.03.016

Subject(s) - ulcerative colitis , adalimumab , term (time) , medicine , maintenance therapy , intensive care medicine , tumor necrosis factor alpha , chemotherapy , disease , physics , quantum mechanics

Adalimumab is a recombinant human IgG1 monoclonal antibody to TNF-alpha. There are limited data with regard to its efficacy in ulcerative colitis. We report experience of adalimumab in ulcerative colitis in a single centre with a focus on the ability of this agent to maintain response and avoid colectomy in the medium to long-term.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research